Goodwin's Sophie McGrath, Arvin Abraham, Anne Stroude, and Mike Grainger write that while the healthcare financing market showed early signs of recovery in 2024, M&A activity remained sluggish for much of the year, only picking up modestly in the second half. As 2025 progresses, declining interest rates, an evolving US political landscape, and the return of big banks to deal lending are setting the stage for a significant rebound. Several countervailing factors also influence this landscape, including persistent geopolitical risks that could derail deal activity and have so far in 2025 muted an expected resurgence of deals. Nevertheless, the sector remains cautiously optimistic, with investors seeking opportunities in resilient healthcare subsectors that balance innovation with financial sustainability. Much of the M&A activity in 2024 was led by corporates and strategic buyers, while private equity investors were constrained by high interest rates and tighter financing conditions. Read the HealthcareMarkets article for more.